American College of Cardiology urges wider use of weight-loss drugs

Published 20/06/2025, 15:18
© Reuters.

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more Americans should be taking weight-loss drugs to prevent heart disease.

The nation’s top cardiology organization now advises that medications like Novo Nordisk (NYSE:NVO) A/S’s Wegovy and Eli Lilly & Co (NYSE:LLY).’s Zepbound should be considered as part of the first line of defense for obese patients, rather than requiring them to try lifestyle modifications first.

This marks a significant shift from previous guidelines that prioritized exercise and diet changes before medication. The new position acknowledges that exercise and clean eating aren’t always sufficient for heart health.

According to the nonprofit medical association, these popular weight-loss drugs are more effective than lifestyle changes alone and carry fewer risks than surgical options in preventing heart disease, which remains the leading cause of death in the United States.

The recommendation is explicitly aimed at influencing insurance companies and federal programs that determine prescription drug coverage. Cardiologists’ support could drive greater patient adoption and broader insurance coverage for these medications.

Novo Nordisk and Eli Lilly are the two primary companies competing in this market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.